ORIC PHARMACEUTICALS INC's ticker is ORIC and the CUSIP is 68622P109. A total of 92 filers reported holding ORIC PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 6.67 and the average weighting 0.6%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2021 | $2,299,000 | -54.4% | 109,945 | -61.4% | 0.03% | -51.7% |
Q2 2021 | $5,041,000 | -27.9% | 284,945 | -0.2% | 0.06% | -35.6% |
Q1 2021 | $6,993,000 | -17.0% | 285,445 | +14.7% | 0.09% | -24.4% |
Q4 2020 | $8,425,000 | +108.5% | 248,898 | +54.0% | 0.12% | +95.1% |
Q3 2020 | $4,041,000 | -25.9% | 161,585 | 0.0% | 0.06% | -26.5% |
Q2 2020 | $5,450,000 | – | 161,585 | – | 0.08% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Memorial Sloan Kettering Cancer Center | 602,272 | $3,643,746 | 14.84% |
Column Group LLC | 3,568,181 | $21,587,495 | 14.33% |
Nextech Invest Ltd. | 4,285,714 | $25,928,570 | 7.86% |
Prosight Management, LP | 2,579,802 | $15,607,802 | 4.95% |
Invus Financial Advisors, LLC | 1,007,575 | $6,095,829 | 3.82% |
SILVERARC CAPITAL MANAGEMENT, LLC | 1,123,345 | $6,796,237 | 2.06% |
VR Adviser, LLC | 2,142,856 | $12,964,279 | 1.36% |
Altium Capital Management LP | 418,706 | $2,533,171 | 1.32% |
Euclidean Capital LLC | 1,978,820 | $11,971,862 | 1.31% |
Frazier Life Sciences Management, L.P. | 2,142,855 | $12,964,273 | 0.86% |